{"filings":[{"id":470237,"accession_number":"0000874716-26-000110","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2026-05-15T20:00:10+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"IDEXX shareholders approve board declassification and 25% special meeting right","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board declassification approved; all directors to be elected annually starting at 2029 annual meeting.","Shareholders owning 25% of stock continuously for at least 1 year can now call a special meeting.","Bylaws amended effective May 13, 2026; certificate of amendment filed with Delaware.","All three Class II director nominees elected: Junius, Kingsley, Vandebroek with >60M votes each.","Shareholder proposal for special meeting right failed with 28M for vs 40M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99324,"accession_number":"0001104659-26-055203","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q1 beats: rev $1.14B (+14%), EPS $3.47 (+17%); raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $1,141M (+14% as reported, +11% organic); EPS $3.47 (+17% as reported, +15% comparable).","CAG Diagnostics recurring revenue +14% as reported, +11% organic; premium instrument installed base +12%.","FY2026 revenue guidance raised $42M at midpoint to $4,675-$4,760M; EPS guidance to $14.45-$14.90.","Organic revenue growth guidance raised to 7.7%-9.7% from 7.0%-9.0%; operating margin expansion 50-90 bps.","CEO Jay Mazelsky to transition; Mike Erickson will continue as a key leader (mentioned in earnings release)."],"consensus_eps_estimate":null,"consensus_eps_actual":3.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":1140820000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115256,"accession_number":"0001104659-26-034906","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"IDEXX EVP Nimrata Hunt to depart Apr 13; position eliminated, advisory role until Jul 13","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nimrata Hunt, EVP Global Strategy & Commercial, steps down effective Apr 13, 2026; position eliminated.","Advisory role from Apr 13 to Jul 13, 2026; per diem pay based on current base salary.","Separation benefits: $1.23M salary continuation (104 weeks), $984K bonus (2 years), plus COBRA; ~$2.29M total.","All unvested equity awards forfeited as of Jul 13; vested options remain exercisable per award terms.","No successor named; restructuring of global strategy & commercial function."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115255,"accession_number":"0000874716-26-000007","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director M. Anne Szostak to retire from IDEXX Board effective May 12, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Szostak notified Board on Feb 13, 2026; retirement effective after 2026 Annual Meeting.","Szostak has served since 2012; departure not due to any disagreement with Company or Board.","Board reduces Class III size upon her retirement; overall Board unchanged by prior appointment of Michael G. Erickson as Class II member."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115254,"accession_number":"0001104659-26-008904","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q4 revenue $1.09B (+14% YoY), EPS $3.08 (+18%); guides FY26 rev $4.63B-$4.72B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $1,091M (+14% as reported, +12% organic); EPS $3.08 (+18% as reported, +17% comparable).","Full year 2025 revenue $4,304M (+10%); EPS $13.08 (+23% reported, +14% comparable).","CAG Diagnostics recurring revenue grew 12% reported; record >1,900 IDEXX inVue Dx placements in Q4.","FY26 guidance: rev $4,632M-$4,720M (7.6%-9.6% reported growth); EPS $14.29-$14.80 (9%-13% growth).","Operating margin expanded 150 bps reported in Q4 to 28.9%; gross margin 60.3%, up 50 bps."],"consensus_eps_estimate":null,"consensus_eps_actual":13.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":4303702000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115253,"accession_number":"0001104659-26-003103","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"IDEXX CEO succession: Mike Erickson to become President and CEO on May 12, 2026; Mazelsky to Executive Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jay Mazelsky steps down as CEO effective May 12, 2026, transitions to Executive Chair; will retire from board in May 2027.","Michael Erickson, PhD (EVP & GM Global Point of Care), promoted to President and CEO, joining the board.","Erickson's compensation: $1M base salary, 120% target bonus, FY2026 equity target at least $7.8M (50% options, 50% PSUs).","Mazelsky's Executive Chair compensation: $1.15M base, blended bonus target, $8.275M RSU grant in Feb 2026.","Lawrence Kingsley, currently Non-Executive Chair, becomes independent Lead Director after transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131676,"accession_number":"0001104659-25-111278","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"IDEXX amends credit facility: extends revolver to 2030, adds $250M term loan due 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment extends $1.0B revolver maturity to 5 years from Nov 12, 2025; adds $250M term loan due 3 years from closing.","IDEXX Holdings II GmbH (Switzerland) added as new borrower under the credit agreement.","Departing lenders repaid; new lenders join; interest rates tied to consolidated leverage ratio.","Incremental capacity of up to $250M retained for future revolving or term loans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131675,"accession_number":"0001104659-25-105185","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q3 revenue $1.1B (+13%), EPS $3.40 (+21%); raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,105M (+13% reported, +12% organic); CAG Diagnostics recurring revenue +11% reported, +10% organic.","EPS $3.40 (+21% reported, +15% comparable); operating margin 32.1%, +100 bps reported.","Raises FY2025 revenue guidance to $4,270-$4,300M (midpoint +$43M) and EPS guidance to $12.81-$13.01 (midpoint +$0.33).","Over 1,700 IDEXX inVue Dx placements in Q3; strong capital instrument revenue growth of 74% reported.","Updated FY2025 organic revenue growth outlook 8.8%-9.5%; comparable margin expansion guidance raised to 80-100 bps."],"consensus_eps_estimate":null,"consensus_eps_actual":9.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":3213123000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131674,"accession_number":"0001104659-25-097319","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"IDEXX elects Karen Peacock as independent Class I director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Karen Peacock elected independent Class I director, effective October 6, 2025, filling a newly created seat.","She will serve on Compensation and Talent Committee and Finance Committee; standard director compensation applies prorated.","Peacock is former CEO of Intercom, ex-SVP at Intuit, and currently lead independent director at Dropbox.","Board expanded from ten to eleven directors; she will stand for election at 2027 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148241,"accession_number":"0001104659-25-073304","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q2 EPS $3.63 (+49% reported); raises FY2025 revenue and EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $1,109M (+11% reported, +9% organic); CAG Diagnostics recurring revenue +9% reported, +7% organic.","Record quarterly instrument placements including nearly 2,400 IDEXX inVue Dx units.","FY2025 revenue guidance raised to $4,205M-$4,280M (prior $4,095M-$4,210M); organic growth outlook 7.0%-9.0%.","FY2025 EPS guidance raised to $12.40-$12.76 (prior $11.93-$12.43); reported growth 16%-20%.","Operating margin guidance improved to 31.3%-31.6%; comparable expansion 50-80 bps."],"consensus_eps_estimate":null,"consensus_eps_actual":6.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":2107884000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148240,"accession_number":"0001104659-25-066840","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"IDEXX elects former State Street CEO Joseph L. Hooley to Board; board expands to 10","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph L. (Jay) Hooley elected as independent Class III Director effective July 10, 2025.","Hooley served as Chair and CEO of State Street Corporation (2011-2019 / 2010-2018).","Board expanded from 9 to 10 directors; Hooley appointed to Audit and Governance & Corporate Responsibility Committees.","Hooley also serves on boards of Exxon Mobil Corporation and Aptiv PLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167010,"accession_number":"0000874716-25-000085","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"IDEXX shareholders approve charter amendments removing supermajority, officer exculpation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Elimination for Series A Preferred Stock; preferred shares revert to undesignated status.","Shareholders approved removal of supermajority voting provisions from the certificate of incorporation.","Shareholders approved amendment allowing officer exculpation under Delaware law.","Board amended bylaws to include exclusive forum provision for Delaware courts and update procedural rules.","Elected Stuart Essig, Jonathan Mazelsky, M. Anne Szostak as Class III directors for terms until 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167009,"accession_number":"0001104659-25-042955","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q1 EPS $2.96 (+5%), rev $998M (+4%); raises FY25 revenue & EPS outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $998M (+4% reported, +5% organic); EPS $2.96 (+5%, +7% comparable).","CAG Diagnostics recurring revenue +3% reported, +4.5% organic; VetLab consumables organic +10%.","Launched IDEXX Cancer Dx for early canine lymphoma detection in North American reference labs.","FY25 revenue guidance raised to $4,095M-$4,210M; EPS guidance raised to $11.93-$12.43 ($0.19 increase).","FY25 organic revenue growth outlook maintained at 6%-9%; comparable EPS growth maintained at 8%-12%."],"consensus_eps_estimate":null,"consensus_eps_actual":2.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":998427000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184386,"accession_number":"0000874716-25-000011","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"IDEXX director Asha Collins resigns from Board, effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Asha Collins resigned from the Board of Directors on February 13, 2025.","Resignation was not due to any disagreement with the Company on operations, policies, or practices.","Board size reduced from ten to nine directors following the resignation.","Company and Board thanked Dr. Collins for her service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184385,"accession_number":"0001104659-25-008331","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q4 revenue $954M (+6% YoY), EPS $2.62; guides 2025 rev $4.06-$4.17B, EPS $11.74-$12.24","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $954M (+6% reported and organic); CAG Diagnostics recurring revenue +7% organic.","Q4 EPS $2.62 (+13% as reported, +10% comparable); full year EPS $10.67 (+12% comparable).","2025 revenue guidance $4.055-$4.170B (+4-7% reported, +6-9% organic); EPS $11.74-$12.24 (+10-15% reported).","Expects ~$1.5B in share repurchases in 2025 (~4% of market cap), subject to market conditions.","2024 full year revenue $3.898B (+6% as reported and organic); targets 200-250 bps operating margin improvement in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":10.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":3897504000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200987,"accession_number":"0000874716-24-000150","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"IDEXX Laboratories adopts nonqualified deferred compensation plan for select management and highly compensated employees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Participants may defer 5–50% of base salary, 5–100% of annual bonus, and 5–100% of stock units.","Cash deferrals fully vested; stock unit deferrals vest per award agreement; discretionary company contributions may vest on change in control, death, disability, or retirement.","Company currently has no intention to make discretionary contributions; distributions occur upon separation, specified date, death, or unforeseeable emergency.","Stock unit deferrals settled in shares; cash deferrals deemed invested in participant-chosen options; all accounts are unfunded unsecured promises.","Plan effective Dec 6, 2024; administered by Compensation and Talent Committee and Employee Plans Administrative Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200986,"accession_number":"0000874716-24-000148","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IDEXX boosts share repurchase authorization by 5M shares, adds to 1.3M remaining","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to five million additional shares of common stock.","New authorization is in addition to the 1.3 million shares remaining under prior approval as of Dec 3, 2024.","Repurchases may be made in open market or negotiated transactions; program has no expiration date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200985,"accession_number":"0001104659-24-121326","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"IDEXX CFO Brian McKeon to retire June 2025; Andrew Emerson named successor effective March 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["McKeon will retire June 1, 2025; will step down as CFO March 1, 2025 and serve as Special Advisor until retirement.","Andrew Emerson appointed EVP, CFO and Treasurer effective March 1, 2025; previously SVP Corporate and CAG Finance.","Emerson's compensation: base salary $550K, target bonus 75% of salary, eligible for annual equity grants, change-in-control benefits.","McKeon oversaw significant growth; Emerson has nine years at IDEXX leading CAG finance and corporate finance since 2020.","Company reaffirmed full-year 2024 guidance as provided on October 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200984,"accession_number":"0001104659-24-116365","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Board member Jonathan W. Ayers resigns from IDEXX Board effective Nov 8, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ayers resigned from Board and Finance Committee effective November 8, 2024.","Ayers served as Chairman, President and CEO from 2002-2019; non-employee director since 2019.","Resignation not due to any disagreement with company's operations, policies, or practices.","Board size reduced from 11 to 10 directors; no replacement named."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200983,"accession_number":"0000874716-24-000142","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"IDEXX extends Ortho-Clinical Diagnostics supply agreement to 2044, revises pricing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IDEXX entered U.S. and European supply agreement amendments with Ortho-Clinical Diagnostics for dry slides used in veterinary chemistry analyzers.","Expiration dates of both agreements extended to end of 2044.","Pricing arrangements modified, including volume tiers and pricing over contract terms.","Amendments effective as of October 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200982,"accession_number":"0001104659-24-112826","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q3 EPS $2.80, revenue $976M; cuts FY24 revenue guidance citing macro headwinds","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $976M (+7% reported, +6% organic); EPS $2.80 (+11% reported, +12% comparable).","CAG Diagnostics recurring revenue +7% reported and organic; global premium instrument installed base +10% YoY.","FY24 revenue guidance cut $38M at midpoint to $3,865M-$3,890M; organic growth now 5.3%-6.0% (prior 6.2%-7.8%).","EPS guidance narrowed to $10.37-$10.53, midpoint unchanged; $0.56 negative impact from litigation accrual.","Water revenue +13%; LPD -3%. Gross margin 61.1% (+120 bps). Operating margin 31.2% (+110 bps)."],"consensus_eps_estimate":null,"consensus_eps_actual":8.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":2943216000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200981,"accession_number":"0001104659-24-112975","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K/A","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX corrects FY24 comparable margin expansion to 30-60 bps (from 70-100 bps); Q3 EPS $2.80","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Corrected 2024 comparable operating profit margin expansion to 30-60 bps from 70-100 bps (error in prior release).","Q3 revenue $976M (+7% reported, +6% organic); CAG Diagnostics recurring revenue +7%.","Q3 diluted EPS $2.80, +11% as reported, +12% comparable basis; operating margin 31.2%.","Updated FY24 revenue guidance to $3.865B-$3.890B (~1% lower at midpoint); EPS narrowed to $10.37-$10.53.","FY24 organic revenue growth now 5.3%-6.0% (prior 6.2%-7.8%) due to softer U.S. clinic visit trends."],"consensus_eps_estimate":null,"consensus_eps_actual":8.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":2943216000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216997,"accession_number":"0001104659-24-086074","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q2 rev +6% to $1,004M; EPS $2.44; cuts FY guidance on litigation charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,004M, +6% reported (+7% organic); CAG Diagnostics recurring +6% reported (+7% organic).","EPS $2.44, down 9% reported; comparable +15% excluding $0.56/share discrete litigation accrual.","Record Q2 premium instrument placements; global premium instrument installed base grew 11% YoY.","FY2024 guidance updated: revenue $3,885M-$3,945M (6.2-7.8% organic); EPS $10.31-$10.59, down $0.56 at midpoint.","$62M discrete litigation expense accrual hit operating margin by ~610 bps and EPS by $0.56."],"consensus_eps_estimate":null,"consensus_eps_actual":5.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":1967673000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236749,"accession_number":"0000874716-24-000107","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"IDEXX enters $25K/month consulting pact with retired EVP; all annual meeting proposals pass","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Retired EVP James Polewaczyk to provide coaching; $25,000/month for one-year term starting May 7, 2024.","All four Class I director nominees elected: Britt, Claflin, Collins, Samad with >64M votes each.","Advisory vote on executive compensation approved: 64.3M for, 4.4M against.","Shareholder proposal for simple majority vote passed: 61.4M for, 6.4M against.","Ratification of PwC as auditor approved: 70.5M for, 3.9M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236748,"accession_number":"0001104659-24-055201","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q1 revenue $964M (+7%), EPS $2.81; cuts 2024 revenue/EPS guidance on FX and visit slowdown","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $964M (+7% as reported and organic); EPS $2.81 (+10% reported, +9% comparable).","CAG Diagnostics recurring revenue grew 7% as reported and organic; global premium instrument installed base up 11% YoY.","FY2024 revenue guidance lowered to $3,895M-$3,965M (prior $3,930M-$4,040M); EPS guidance lowered to $10.82-$11.20.","Guidance cut reflects ~$35M FX headwind and reduction of 1% from high end of organic growth range due to US clinical visit moderation.","Gross margin improved 120bps to 61.5%; operating margin contracted 10bps to 31.0% due to lapping a Q1 2023 customer contract resolution payment."],"consensus_eps_estimate":null,"consensus_eps_actual":2.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":964095000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254370,"accession_number":"0001157523-24-000165","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q4 revenue $902M (+9%); FY24 guides $3.93-4.04B, EPS $10.84-11.33","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $902M, up 9% reported and 8% organic; CAG Diagnostics recurring revenue +11% reported and +10% organic.","Q4 EPS $2.32, up 13% reported and 17% on a comparable basis; full-year EPS $10.06 (+25% reported).","FY24 revenue guidance $3.93B-$4.04B (+7.5%-10.5% reported); EPS $10.84-$11.33 (+8%-13% comparable).","Full-year operating margin expanded 330 bps reported; FY24 operating margin target 30.2%-30.7%.","New IDEXX inVue Dx slide-free cellular analyzer launch targeted for late 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":10.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":3660953000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271857,"accession_number":"0000874716-23-000143","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"IDEXX EVP and Chief Commercial Officer James Polewaczyk to retire April 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James F. Polewaczyk, EVP and Chief Commercial Officer, notified retirement on Dec 5, 2023.","Effective date of retirement is April 1, 2024, after 17 years of service.","No replacement has been announced; search process not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271856,"accession_number":"0001157523-23-001588","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q3 revenue $916M (+9% reported); EPS $2.53; FY guidance updated to $3.635-$3.65B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $916M (+9% reported, +8% organic) driven by CAG Diagnostics recurring revenue +10% reported (+9% organic).","EPS $2.53, up 18% reported (16% comparable); operating margin 30.1% (expanded 100bps reported, 140bps comparable).","FY2023 revenue guidance lowered to $3,635-$3,650M (7.9%-8.4% growth); EPS outlook raised to $9.74-$9.90 (midpoint +$0.05).","Global premium instrument installed base grew 11% YoY; VetLab consumables revenue +11% organic.","Water revenue +7% organic; Livestock/Poultry/Dairy revenue +2% organic; solid gains in U.S. offset international headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":7.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":2759352000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288698,"accession_number":"0001157523-23-001198","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q2 revenue $944M (+10% organic); EPS $2.67 (+71%); raises 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $944M, +10% reported and organic; CAG Diagnostics recurring revenue +11% reported, +12% organic.","EPS $2.67, +71% reported (+77% comparable); includes $0.04 tax benefit and $0.07 negative FX impact.","Record quarterly premium instrument placements; global installed base grew 11% annually.","Updated 2023 revenue guidance to $3,660M-$3,715M (8.5%-10% growth), EPS guidance to $9.64-$9.90 (20%-23% reported growth)."],"consensus_eps_estimate":null,"consensus_eps_actual":5.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":1843825000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288697,"accession_number":"0000874716-23-000092","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2023-07-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"IDEXX Laboratories elects Irene Chang Britt to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Irene Chang Britt elected as independent Class I Director, effective July 11, 2023.","She will serve on the Audit Committee and Compensation and Talent Committee.","Board size increased from 10 to 11 directors; she will stand for election at 2024 annual meeting.","Former Campbell Soup executive (President/Divisional CEO, Pepperidge Farm) and current director at Brighthouse Financial and Victoria's Secret.","Director compensation updated: cash retainer raised to $90,000, equity award to $250,000 annually."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309332,"accession_number":"0000874716-23-000074","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"IDEXX shareholders re-elect three Class II directors and approve say-on-pay at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors Junius, Kingsley, and Vandebroek elected as Class II directors with >61M votes each.","Ratification of PricewaterhouseCoopers as independent auditor approved (69.3M for, 5.0M against).","Advisory vote to approve executive compensation passed (65.4M for, 3.5M against).","Board adopts annual say-on-pay frequency based on shareholder preference (64.0M voted for one year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309331,"accession_number":"0001157523-23-000670","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q1 revenue $900M (+8% reported, +10% organic); EPS $2.55; raises 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $900M, up 8% reported, 10% organic; CAG Diagnostics recurring revenue up 9% reported, 12% organic.","EPS $2.55, up 12% reported, 18% comparable; includes $0.06 tax benefit and $0.11 negative FX impact.","Raises FY2023 revenue guidance to $3,615M-$3,700M (7.5%-10%) and EPS guidance to $9.33-$9.75 (16%-22% reported).","Record Q1 global premium instrument placements; U.S. CAG Diagnostics organic recurring revenue grew 14%, 1,350 bps premium to clinic visits.","Operating margin 31.1%, up 150 bps reported, 210 bps comparable; gross margin 60.3%, up 70 bps reported."],"consensus_eps_estimate":null,"consensus_eps_actual":2.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":900195000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328069,"accession_number":"0000950170-23-001820","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2023-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q4 revenue +7% organic; EPS $2.05; FY23 guidance rev $3.59B-$3.69B, EPS $9.27-$9.75","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $829M (+3% reported, +7% organic); EPS $2.05 (+8% reported, +14% comparable).","FY2022 revenue $3,367M (+5% reported, +7% organic); EPS $8.03 (-7% reported, -1% comparable, including discrete R&D headwind).","CAG Diagnostics recurring revenue grew 4% reported, 8% organic in Q4; global premium instrument installed base up 13% YoY.","FY2023 guidance: revenue $3.59B-$3.69B (6.5%-9.5% reported growth); EPS $9.27-$9.75 (16%-21% reported growth).","Q4 operating margin 27.3% (+240bps reported); 2023 operating margin target 29.0%-29.6%."],"consensus_eps_estimate":null,"consensus_eps_actual":8.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":3367324000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345725,"accession_number":"0000950123-22-010618","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q3 revenue $842M (+8% organic); EPS $2.15 (+13% comparable); updates FY2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $842M, +4% reported, +8% organic; CAG Diagnostics recurring revenue +5% reported, +9% organic.","EPS $2.15, +6% reported, +13% comparable; operating margin 29.1%, +100 bps comparable.","Record global premium instrument placements, +10% YoY; installed base +14%.","FY2022 guidance: revenue growth 3.5-4.5% reported, 6.5-7.5% organic; EPS $7.74-$7.98.","Foreign currency headwinds: ~4% revenue impact, ~$0.25 EPS impact for FY2022."],"consensus_eps_estimate":null,"consensus_eps_actual":5.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":2538756000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345724,"accession_number":"0001193125-22-266779","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2022-10-21T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"IDEXX amends credit agreement, adds $250M term loan and SOFR conversion","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $250M incremental term loan on Oct 20, 2022 under amended credit facility.","Total capacity increased to up to $1.5B with option for additional $250M term/revolver.","Existing LIBOR-based borrowings will convert to SOFR-based upon interest period expiry.","Interest rates based on SOFR plus margin 0.875%-1.375% depending on leverage ratio.","Covenants reaffirmed; no event of default; obligations remain in full force."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362134,"accession_number":"0001564590-22-027326","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q2 revenue $861M +4% reported; EPS $1.56 -33%; cuts FY2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $861M, up 4% reported and 6.5% organic; CAG Diagnostics recurring revenue +4% reported, +7% organic.","EPS $1.56, down 33% as reported, including $0.72 impact from $80M discrete R&D investments.","Record Q2 premium instrument placements up 18% YoY; global installed base +15%.","Updated FY2022 revenue guidance $3,305-$3,385M (3%-5.5% reported, 5.5%-8% organic); EPS $7.77-$8.05.","U.S. same-store clinical visits declined 3% in Q2 vs +13% prior year; diagnostics revenue +6% same-store."],"consensus_eps_estimate":null,"consensus_eps_actual":3.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":1697095000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362133,"accession_number":"0000874716-22-000028","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2022-07-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"IDEXX amends bylaws to align director nomination notice with SEC Rule 14a-19","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended Section 1.10 to require stockholders to represent they intend to solicit proxies from holders of at least 67% of voting power.","Prior rule required representation of holding shares reasonably believed sufficient to elect the nominee.","Effective July 13, 2022; other minor non-substantive changes also made."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381654,"accession_number":"0001564590-22-023240","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"IDEXX to wind down Russian subsidiary, end direct operations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue from Russia represented less than 1% of total 2021 consolidated revenue.","No manufacturing or significant supply arrangements in Russia.","Wind-down includes liquidation of the sole Russian subsidiary and direct operations.","Company providing transition support to impacted Russian employees.","Limited products for human or animal health will continue via third-party distributors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381653,"accession_number":"0000874716-22-000023","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2022-05-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"IDEXX shareholders re-elect four directors, ratify auditor, approve executive compensation at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All four Class III director nominees (Ayers, Essig, Mazelsky, Szostak) elected; Mazelsky received 69.9M votes for.","Ratification of PricewaterhouseCoopers as independent auditor passed with 71.7M votes for (94.5% of votes cast).","Advisory vote on named executive officer compensation approved with 66.5M for vs 3.6M against (94.6% support).","Broker non-votes of 5.57M shares existed for director elections and say-on-pay, but not for auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381652,"accession_number":"0001564590-22-017653","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q1 rev $837M (+8%); cuts FY22 EPS guidance to $8.11-$8.35 on vet capacity, forex, R&D charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 EPS $2.27 (-3% reported, +3% comparable); revenue $837M (+8% reported and organic).","CAG Diagnostics recurring revenue +9% organic; record Q1 premium instrument placements; capital instrument rev +22% organic.","FY22 revenue outlook cut to $3,390-$3,465 (5.5%-8% reported growth); organic growth 7.5%-10%.","FY22 EPS outlook $8.11-$8.35 includes $0.72 discrete R&D charge, $0.10 forex, $0.05 interest; prior guidance implied down.","U.S. same-store clinical visits declined 2% in Q1 vs +13% prior year; practice revenue +6% vs +16%."],"consensus_eps_estimate":null,"consensus_eps_actual":2.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":836549000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399639,"accession_number":"0001564590-22-003449","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2022-02-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q4 revenue $801M (+11%), full-year EPS $8.60 (+28%); guides 2022 revenue $3.5-$3.565B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $801M, up 11% reported and 10.5% organic; CAG Diagnostics recurring revenue grew 13%.","Full-year EPS $8.60, up 28% reported and 29% comparable; operating margin expanded 330 bps reported.","Record premium instrument placements drove 14% YoY expansion of global installed base.","Initial 2022 guidance: revenue $3,500M-$3,565M (9-11% growth), EPS $9.27-$9.59 (8-11% growth).","U.S. same-store clinical visit growth 2% in Q4; on a two-year basis, visits up 5.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":8.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":3215360000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418629,"accession_number":"0001193125-21-352679","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2021-12-09T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"IDEXX enters $1B revolving credit facility with extended maturity and lower rates","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Fourth amended & restated credit agreement provides $1B unsecured revolver with $250M accordion feature.","Maturity extended to December 9, 2026 (from 2020 agreement's 3-year term).","Interest rate margins reduced; pricing (LIBOR + 0.875–1.375%) based on consolidated leverage ratio.","New borrowers added: IDEXX Laboratories B.V. (Netherlands) and IDEXX Laboratories GmbH (Switzerland).","Proceeds for general corporate purposes; commitment fee on unused portion ranges 0.075–0.250%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418628,"accession_number":"0001564590-21-053288","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q3 revenue $810M (+12%), EPS $2.03; raises FY2021 guidance to higher end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $810M (+12% reported, +10% organic); EPS $2.03 (+20% reported, +12% comparable).","CAG Diagnostics recurring revenue +13% reported, +11% organic; record Q3 premium instrument placements.","Updates FY2021 guidance: revenue $3,185-3,200M (17.5-18% growth), EPS $8.30-8.38 (24-25% growth).","Operating margin 27.9% (+410bps reported, +20bps comparable); benefited from lapping prior year litigation accrual.","Water revenue +15% reported, +13% organic; LPD revenue declined 21% due to China ASF testing comparison."],"consensus_eps_estimate":null,"consensus_eps_actual":6.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":2414270000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436177,"accession_number":"0001564590-21-039326","cik":874716,"company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","form_type":"8-K","filed_at":"2021-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEXX Q2 revenue $826M (+30% reported, +25% organic); raises FY 2021 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["EPS of $2.34, up 36% as reported and 33% comparable basis.","CAG Diagnostics recurring revenue grew 30% reported, 26% organic.","2021 revenue guidance raised to $3,170M-$3,205M (17%-18.5% reported growth).","2021 EPS outlook raised to $8.20-$8.36; operating margin forecast 28.6%-29.1%.","U.S. same-store clinical visit growth 13% in Q2; premium instrument placements doubled YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":4.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":1603849000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":43463747666.52848,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}